Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 6, 2018

Mallinckrodt enrols first patient in Phase ll trial of MNK-1411

Mallinckrodt has enrolled the first patient in the BRAVE Phase ll trial to evaluate the efficacy and safety of MNK-1411 (cosyntropin) to treat patients with Duchenne Muscular Dystrophy (DMD).

Mallinckrodt has enrolled the first patient in the BRAVE Phase ll trial to evaluate the efficacy and safety of MNK-1411 (cosyntropin) to treat patients with Duchenne Muscular Dystrophy (DMD).

The multicentre, randomised, parallel group, double blind, multiple dose, placebo controlled trial will include male DMD patients aged four to eight years.

As part of the trial, around 30 patients who have a diagnosis of DMD confirmed by complete dystrophin deficiency, or an identifiable mutation in the DMD gene, or complete dystrophin gene sequencing consistent with DMD will be enrolled.

To take part in the trial, the patients must have a typical clinical profile consistent with DMD.

The enrolled patients will be randomly assigned in a 2:1 ratio to receive one of two weight-based doses of MNK-1411, or volume-matched placebo, which will be administered subcutaneously two times a week for 24 weeks.

“Mallinckrodt is focused on meeting the unmet medical needs of patients, particularly those with rare diseases like DMD.”

Upon completion of the 24-week, randomised, double-blind, placebo-controlled treatment period, patients will receive active treatment for an additional 24 weeks under an optional open-label extension phase.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The trial’s key efficacy objectives comprise timed function tests such as a 10m walk/run, four-stair climb and rise from floor, and the NorthStar Ambulatory Assessment.

Mallinckrodt executive vice-president and chief scientific officer Steven Romano said: “Mallinckrodt is focused on meeting the unmet medical needs of patients, particularly those with rare diseases like DMD.”

DMD, which is a genetic disorder characterised by progressive muscle degeneration and weakness, is caused by an absence of dystrophin protein that helps keep muscle cells intact.

It is one of nine types of muscular dystroph and its symptoms are seen in early childhood, usually between ages three and five.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU